Blood product transfusion complications can be categorized into immunological, infective, and other complications. Immunological complications include acute haemolytic reactions, non-haemolytic febrile reactions, and allergic/anaphylaxis reactions. Infective complications may arise due to transmission of vCJD, although measures have been taken to minimize this risk. Other complications include transfusion-related acute lung injury (TRALI), transfusion-associated circulatory overload (TACO), hyperkalaemia, iron overload, and clotting.

Non-haemolytic febrile reactions are thought to be caused by antibodies reacting with white cell fragments in the blood product and cytokines that have leaked from the blood cell during storage. These reactions may occur in 1-2% of red cell transfusions and 10-30% of platelet transfusions. Minor allergic reactions may also occur due to foreign plasma proteins, while anaphylaxis may be caused by patients with IgA deficiency who have anti-IgA antibodies.

Acute haemolytic transfusion reaction is a serious complication that results from a mismatch of blood group (ABO) which causes massive intravascular haemolysis. Symptoms begin minutes after the transfusion is started and include a fever, abdominal and chest pain, agitation, and hypotension. Treatment should include immediate transfusion termination, generous fluid resuscitation with saline solution, and informing the lab. Complications include disseminated intravascular coagulation and renal failure.

TRALI is a rare but potentially fatal complication of blood transfusion that is characterized by the development of hypoxaemia/acute respiratory distress syndrome within 6 hours of transfusion. On the other hand, TACO is a relatively common reaction due to fluid overload resulting in pulmonary oedema. As well as features of pulmonary oedema, the patient may also be hypertensive, a key difference from patients with TRALI.

Plasma cells would be visible in a bone marrow aspirate to diagnose multiple myeloma, which is characterized by osteolytic lesions, decreased renal function, bony pain, and the presence of Bence-Jones proteins. This condition is a type of B-cell neoplasm affecting plasma cells.

Understanding Multiple Myeloma: Features and Investigations

Multiple myeloma is a type of cancer that affects the plasma cells in the bone marrow. It is most commonly found in patients aged 60-70 years. The disease is characterized by a range of symptoms, which can be remembered using the mnemonic CRABBI. These include hypercalcemia, renal damage, anemia, bleeding, bone lesions, and increased susceptibility to infection. Other features of multiple myeloma include amyloidosis, carpal tunnel syndrome, neuropathy, and hyperviscosity.

To diagnose multiple myeloma, a range of investigations are required. Blood tests can reveal anemia, renal failure, and hypercalcemia. Protein electrophoresis can detect raised levels of monoclonal IgA/IgG proteins in the serum, while bone marrow aspiration can confirm the diagnosis if the number of plasma cells is significantly raised. Imaging studies, such as whole-body MRI or X-rays, can be used to detect osteolytic lesions.

The diagnostic criteria for multiple myeloma require one major and one minor criteria or three minor criteria in an individual who has signs or symptoms of the disease. Major criteria include the presence of plasmacytoma, 30% plasma cells in a bone marrow sample, or elevated levels of M protein in the blood or urine. Minor criteria include 10% to 30% plasma cells in a bone marrow sample, minor elevations in the level of M protein in the blood or urine, osteolytic lesions, or low levels of antibodies in the blood. Understanding the features and investigations of multiple myeloma is crucial for early detection and effective treatment.

The diagnosis of multiple myeloma can be supported by the presence of Bence-Jones protein, which is a monoclonal globulin protein produced by neoplastic plasma cells. Anaemia and hypercalcemia, along with the presence of Bence-Jones protein in the urine, make multiple myeloma the most likely diagnosis.

Gout can be diagnosed by examining the contents of a joint fluid aspirate under polarised red light. The urate crystals will appear needle-shaped and negatively birefringent.

Megaloblastic anaemia occurs due to inhibition of DNA synthesis during red blood cell production. A normal mean corpuscular volume (MCV) and serum vitamin B12 level can rule out megaloblastic anaemia.

While patients with non-Hodgkin lymphoma may present with anaemia, it can be ruled out for the time being as the white cell count and platelet count are normal.

Understanding Multiple Myeloma: Features and Investigations

Multiple myeloma is a type of cancer that affects the plasma cells in the bone marrow. It is most commonly found in patients aged 60-70 years. The disease is characterized by a range of symptoms, which can be remembered using the mnemonic CRABBI. These include hypercalcemia, renal damage, anemia, bleeding, bone lesions, and increased susceptibility to infection. Other features of multiple myeloma include amyloidosis, carpal tunnel syndrome, neuropathy, and hyperviscosity.

To diagnose multiple myeloma, a range of investigations are required. Blood tests can reveal anemia, renal failure, and hypercalcemia. Protein electrophoresis can detect raised levels of monoclonal IgA/IgG proteins in the serum, while bone marrow aspiration can confirm the diagnosis if the number of plasma cells is significantly raised. Imaging studies, such as whole-body MRI or X-rays, can be used to detect osteolytic lesions.

The diagnostic criteria for multiple myeloma require one major and one minor criteria or three minor criteria in an individual who has signs or symptoms of the disease. Major criteria include the presence of plasmacytoma, 30% plasma cells in a bone marrow sample, or elevated levels of M protein in the blood or urine. Minor criteria include 10% to 30% plasma cells in a bone marrow sample, minor elevations in the level of M protein in the blood or urine, osteolytic lesions, or low levels of antibodies in the blood. Understanding the features and investigations of multiple myeloma is crucial for early detection and effective treatment.

Methotrexate treatment can lead to megaloblastic macrocytic anemia due to a deficiency of folate.

The patient’s low hemoglobin and high MCV indicate macrocytic anemia, which can be caused by various factors such as alcohol abuse, hypothyroidism, aplastic anemia, and megaloblastic anemia due to a deficiency of vitamin B12 and/or folate. In this case, the patient has a history of rheumatoid arthritis and takes methotrexate weekly, which inhibits dihydrofolate reductase and causes a deficiency of folate. Therefore, folate deficiency is the most probable cause of the patient’s anemia.

Alcohol excess is an incorrect option as it usually requires larger quantities of alcohol to cause macrocytic anemia.

Anaemia of chronic disease is an incorrect option as it typically results in normocytic or microcytic anemia, not macrocytic anemia.

Iron deficiency anemia is an incorrect option as it causes microcytic anemia, and the MCV value would be lower than expected.

Understanding Macrocytic Anaemia

Macrocytic anaemia is a type of anaemia that can be classified into two categories: megaloblastic and normoblastic. Megaloblastic anaemia is caused by a deficiency in vitamin B12 or folate, which leads to the production of abnormally large red blood cells in the bone marrow. This type of anaemia can also be caused by certain medications, alcohol, liver disease, hypothyroidism, pregnancy, and myelodysplasia.

On the other hand, normoblastic anaemia is caused by an increase in the number of immature red blood cells, known as reticulocytes, in the bone marrow. This can occur as a result of certain medications, such as methotrexate, or in response to other underlying medical conditions.

It is important to identify the underlying cause of macrocytic anaemia in order to provide appropriate treatment. This may involve addressing any nutritional deficiencies, managing underlying medical conditions, or adjusting medications. With proper management, most cases of macrocytic anaemia can be successfully treated.

Leukaemia is a type of cancer that affects the blood and bone marrow. There are two main types of leukaemia: acute and chronic. Acute leukaemia progresses quickly and requires immediate treatment, while chronic leukaemia progresses more slowly and may not require treatment for some time.

There are also different subtypes of leukaemia based on the type of blood cell affected. Acute lymphocytic leukaemia is the most common type of leukaemia in children, while acute myeloid leukaemia is less common. In adults, chronic lymphocytic leukaemia is the most common type, followed by chronic myeloid leukaemia and acute myeloid leukaemia.

Understanding Chronic Lymphocytic Leukaemia: Symptoms and Diagnosis

Chronic lymphocytic leukaemia (CLL) is a type of cancer that affects the blood and bone marrow. It is caused by the abnormal growth of B-cells, a type of white blood cell. CLL is the most common form of leukaemia in adults and is often asymptomatic, meaning it may be discovered incidentally during routine blood tests. However, some patients may experience symptoms such as weight loss, anorexia, bleeding, infections, and lymphadenopathy.

To diagnose CLL, doctors typically perform a full blood count to check for lymphocytosis, a condition where there is an abnormally high number of lymphocytes in the blood. Patients may also have anaemia or thrombocytopenia, which can occur due to bone marrow replacement or autoimmune hemolytic anaemia. A blood film may also be taken to look for smudge cells, which are abnormal lymphocytes that appear broken or fragmented.

The key investigation for CLL diagnosis is immunophenotyping, which involves using a panel of antibodies specific for CD5, CD19, CD20, and CD23. This test helps to identify the type of lymphocyte involved in the cancer and can confirm the diagnosis of CLL. With early detection and proper treatment, patients with CLL can manage their symptoms and improve their quality of life.

ESR and its association with diseases

Erythrocyte sedimentation rate (ESR) is a laboratory test that measures the rate at which red blood cells settle in a tube over a period of time. Elevated ESR levels are often associated with inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus, and polymyalgia rheumatica. In these conditions, the body’s immune system is activated, leading to inflammation and tissue damage. Malignancies such as myeloma can also cause an increase in ESR levels, particularly in females and with increasing age.

On the other hand, low ESR levels are seen in conditions such as polycythaemia, where there is an excess of red blood cells in the body. It is important to note that ESR is not a specific diagnostic test and must be interpreted in conjunction with other clinical findings. Multiple myeloma, a type of plasma cell neoplasm, is the most common haematological malignancy and can lead to a range of symptoms such as hypercalcaemia, renal failure, anaemia, and bone pain. While it is not curable, advances in treatment have significantly improved the median survival of patients. the association between ESR and various diseases can aid in the diagnosis and management of these conditions.

Lead poisoning can cause the accumulation of lead in the metaphysis of bones, which can be seen as bands of increased density on x-rays. In this case, the child’s recent deterioration in academic and physical performance, along with the history of moving to an old house, suggests the possibility of lead-based paint exposure. The presence of a lead line on the gums further supports this suspicion. While normocytic anemia can have many causes, the addition of radiodense lines in the metaphysis of long bones increases the likelihood of lead poisoning. Cretinism, caused by maternal hypothyroidism, typically presents earlier and has different symptoms. Osteomyelitis, an infection of the bone, has different x-ray findings. Sickle cell anemia and iron deficiency are not associated with the symptoms and x-ray findings in this case.

Lead poisoning is a condition that should be considered when a patient presents with abdominal pain and neurological symptoms, along with acute intermittent porphyria. This condition is caused by defective ferrochelatase and ALA dehydratase function. Symptoms of lead poisoning include abdominal pain, peripheral neuropathy (mainly motor), neuropsychiatric features, fatigue, constipation, and blue lines on the gum margin (which is rare in children and only present in 20% of adult patients).

To diagnose lead poisoning, doctors typically measure the patient’s blood lead level, with levels greater than 10 mcg/dl considered significant. A full blood count may also be performed, which can reveal microcytic anemia and red cell abnormalities such as basophilic stippling and clover-leaf morphology. Additionally, raised serum and urine levels of delta aminolaevulinic acid may be seen, which can sometimes make it difficult to differentiate from acute intermittent porphyria. Urinary coproporphyrin is also increased, while urinary porphobilinogen and uroporphyrin levels are normal to slightly increased. In children, lead can accumulate in the metaphysis of the bones, although x-rays are not typically part of the standard work-up.

Various chelating agents are currently used to manage lead poisoning, including dimercaptosuccinic acid (DMSA), D-penicillamine, EDTA, and dimercaprol. These agents work to remove the lead from the body and can help alleviate symptoms.

Prognostic Factors in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a type of cancer that affects the blood and bone marrow. The APML subtype of AML has a higher five-year survival rate of 70% compared to the average rate of 25%. However, it is a medical emergency upon presentation due to the risk of coagulopathy, tumor lysis, and life-threatening infections. Urgent treatment with ATRA chemotherapy is necessary. Younger patients tend to have a better prognosis and can tolerate intensive chemotherapy better. Certain cytogenetic changes, such as t(15;17) in APML and t(8;21) and inv(16), are associated with a favorable prognosis. However, complex cytogenetics are not. A performance status of 3, which indicates that an individual spends more than 50% of the day in bed, is not ideal for intensive chemotherapy. AML that arises from a pre-existing condition, such as a myeloproliferative neoplasm, has a worse prognosis than AML that arises de novo.

Overall, the prognostic factors in AML is crucial for determining the appropriate treatment plan and predicting outcomes.

GVHD occurs when T cells from the donor tissue attack the recipient’s cells. This often manifests as skin and gastrointestinal symptoms in a host who lacks T cells, following a bone marrow or stem cell transplant. The immune response is initiated by donor CD4+ T cells recognizing the recipient’s MHC II as foreign, while donor CD8+ T cells cause tissue damage.

Understanding Graft Versus Host Disease

Graft versus host disease (GVHD) is a complication that can occur after bone marrow or solid organ transplantation. It happens when the T cells in the donor tissue attack the recipient’s cells. This is different from transplant rejection, where the recipient’s immune cells attack the donor tissue. GVHD is diagnosed using the Billingham criteria, which require that the transplanted tissue contains functioning immune cells, the donor and recipient are immunologically different, and the recipient is immunocompromised.

The incidence of GVHD varies, but it can occur in up to 50% of patients who receive allogeneic bone marrow transplants. Risk factors include poorly matched donor and recipient, the type of conditioning used before transplantation, gender disparity between donor and recipient, and the source of the graft.

Acute and chronic GVHD are considered separate syndromes. Acute GVHD typically occurs within 100 days of transplantation and affects the skin, liver, and gastrointestinal tract. Chronic GVHD may occur after acute disease or arise de novo and has a more varied clinical picture.

Diagnosis of GVHD is largely clinical and based on the exclusion of other pathology. Signs and symptoms of acute GVHD include a painful rash, jaundice, diarrhea, nausea, vomiting, and fever. Chronic GVHD can affect the skin, eyes, gastrointestinal tract, and lungs.

Treatment of GVHD involves immunosuppression and supportive measures. Intravenous steroids are the mainstay of treatment for severe cases of acute GVHD, while extended courses of steroid therapy are often needed in chronic GVHD. Second-line therapies include anti-TNF, mTOR inhibitors, and extracorporeal photopheresis. Topical steroid therapy may be sufficient in mild disease with limited cutaneous involvement. However, excessive immunosuppression may increase the risk of infection and limit the beneficial graft-versus-tumor effect of the transplant.

Organised collections of macrophages are known as granulomas.

Chronic inflammation can occur as a result of acute inflammation or as a primary process. There are three main processes that can lead to chronic inflammation: persisting infection with certain organisms, prolonged exposure to non-biodegradable substances, and autoimmune conditions involving antibodies formed against host antigens. Acute inflammation involves changes to existing vascular structure and increased permeability of endothelial cells, as well as infiltration of neutrophils. In contrast, chronic inflammation is characterized by angiogenesis and the predominance of macrophages, plasma cells, and lymphocytes. The process may resolve with suppuration, complete resolution, abscess formation, or progression to chronic inflammation. Healing by fibrosis is the main result of chronic inflammation. Granulomas, which consist of a microscopic aggregation of macrophages, are pathognomonic of chronic inflammation and can be found in conditions such as colonic Crohn’s disease. Growth factors released by activated macrophages, such as interferon and fibroblast growth factor, may have systemic features resulting in systemic symptoms and signs in individuals with long-standing chronic inflammation.

The spleen is responsible for breaking down most of the red blood cells. This is achieved through the action of macrophages that identify and eliminate old red blood cells. It is worth noting that in a healthy individual, the liver, kidneys, and blood vessels do not participate in the breakdown of red blood cells. Additionally, while the bone marrow plays a crucial role in producing blood cells, it is not involved in the destruction of red blood cells.

Understanding Haemolytic Anaemias by Site

Haemolytic anaemias can be classified by the site of haemolysis, either intravascular or extravascular. In intravascular haemolysis, free haemoglobin is released and binds to haptoglobin. As haptoglobin becomes saturated, haemoglobin binds to albumin forming methaemalbumin, which can be detected by Schumm’s test. Free haemoglobin is then excreted in the urine as haemoglobinuria and haemosiderinuria. Causes of intravascular haemolysis include mismatched blood transfusion, red cell fragmentation due to heart valves, TTP, DIC, HUS, paroxysmal nocturnal haemoglobinuria, and cold autoimmune haemolytic anaemia.

On the other hand, extravascular haemolysis occurs when red blood cells are destroyed by macrophages in the spleen or liver. This type of haemolysis is commonly seen in haemoglobinopathies such as sickle cell anaemia and thalassaemia, hereditary spherocytosis, haemolytic disease of the newborn, and warm autoimmune haemolytic anaemia.

It is important to understand the site of haemolysis in order to properly diagnose and treat haemolytic anaemias. While both intravascular and extravascular haemolysis can lead to anaemia, the underlying causes and treatment approaches may differ.

Lymphatic Drainage of the Tongue

The lymphatic drainage of the tongue varies depending on the location of the tumour. The anterior two-thirds of the tongue have minimal communication of lymphatics across the midline, resulting in metastasis to the ipsilateral nodes being more common. On the other hand, the posterior third of the tongue has communicating networks, leading to early bilateral nodal metastases being more common in this area.

The tip of the tongue drains to the submental nodes and then to the deep cervical nodes, while the mid portion of the tongue drains to the submandibular nodes and then to the deep cervical nodes. If mid tongue tumours are laterally located, they will usually drain to the ipsilateral deep cervical nodes. However, those from more central regions may have bilateral deep cervical nodal involvement. Understanding the lymphatic drainage of the tongue is crucial in determining the spread of tumours and planning appropriate treatment.

DIC is a severe and life-threatening complication that typically presents as a late sign of sepsis. The coagulation profile can confirm the diagnosis by revealing specific abnormalities, such as a prolonged prothrombin time indicating a bleeding tendency, depleted fibrinogen levels due to clot formation, and elevated D-dimer levels indicating the body’s efforts to dissolve clots.

Understanding Disseminated Intravascular Coagulation

Under normal conditions, the coagulation and fibrinolysis processes work together to maintain hemostasis. However, in cases of disseminated intravascular coagulation (DIC), these processes become dysregulated, leading to widespread clotting and bleeding. One of the critical factors in the development of DIC is the release of tissue factor (TF), a glycoprotein found on the surface of various cell types. TF is normally not in contact with the circulation but is exposed after vascular damage or in response to cytokines and endotoxins. Once activated, TF triggers the extrinsic pathway of coagulation, leading to the activation of the intrinsic pathway and the formation of clots.

DIC can be caused by various factors, including sepsis, trauma, obstetric complications, and malignancy. Diagnosis of DIC typically involves a blood test that shows decreased platelet count and fibrinogen levels, prolonged prothrombin time and activated partial thromboplastin time, and increased fibrinogen degradation products. Microangiopathic hemolytic anemia may also be present, leading to the formation of schistocytes.

Overall, understanding the pathophysiology and diagnosis of DIC is crucial for prompt and effective management of this potentially life-threatening condition.

Understanding Acute Lymphoblastic Leukaemia

Acute lymphoblastic leukaemia (ALL) is a type of cancer that commonly affects children, accounting for 80% of childhood leukaemias. It is most prevalent in children aged 2-5 years, with boys being slightly more affected than girls. Symptoms of ALL can be divided into those caused by bone marrow failure, such as anaemia, neutropaenia, and thrombocytopenia, and other features like bone pain, splenomegaly, hepatomegaly, fever, and testicular swelling.

There are three types of ALL: common ALL, T-cell ALL, and B-cell ALL. Common ALL is the most common type, accounting for 75% of cases, and is characterized by the presence of CD10 and pre-B phenotype. T-cell ALL accounts for 20% of cases, while B-cell ALL accounts for only 5%.

Certain factors can affect the prognosis of ALL, including age, white blood cell count at diagnosis, T or B cell surface markers, race, and sex. Children under 2 years or over 10 years of age, those with a WBC count over 20 * 109/l at diagnosis, and those with T or B cell surface markers, non-Caucasian, and male sex have a poorer prognosis.

Understanding the different types and prognostic factors of ALL can help in the early detection and management of this cancer. It is important to seek medical attention if any of the symptoms mentioned above are present.

Common Types of Bone Tumours

Osteosarcomas are the most frequent primary bone malignancy, often occurring in the metaphysis around the knee. They are more common in boys and affect those aged between 14 and 20 years old. Symptoms include pain, low impact fracture, or a mass. On an x-ray, they appear as an area of new bone beneath the periosteum, lifting it up, known as Codman’s triangle. Another feature is sunray spiculation, where opaque lines of osteosarcoma grow into adjacent soft tissues.

Chondrosarcoma is a malignant tumour of cartilage that usually develops from benign chondromas, often in hereditary multiple exostoses. Ewing sarcoma is a tumour of unknown origin that develops in limb girdles or the diaphysis of long bones. It has a characteristic onion appearance on x-ray, with concentric rings of new bone formation. Bone metastases are rare in children, and there are no features to suggest a primary tumour, although it should be considered.

Osteoid osteoma is a benign cystic tumour that occurs in the long bones of young men and teenagers. It causes severe pain and shows as local cortical sclerosis but does not invade into soft tissues. the different types of bone tumours and their characteristics is crucial for early detection and treatment.

Von Willebrand’s disease is a genetic cause of coagulation disorders that can result in prolonged bleeding time and nosebleeds. On the other hand, disseminated intravascular coagulation is an acquired condition that does not typically cause increased bleeding time but may occur in patients with sepsis. Acquired hemophilia is also an acquired condition that is not associated with a family history of bleeding disorders. Vitamin K deficiency can lead to increased bleeding time, bruising, and nosebleeds. Reduced liver function can also result in decreased production of clotting factors and an increased risk of bleeding, but this is unlikely to be the cause of the patient’s symptoms based on their medical history.

Understanding Coagulation Disorders

Coagulation disorders refer to conditions that affect the body’s ability to form blood clots. These disorders can be hereditary or acquired. Hereditary coagulation disorders include haemophilia A, haemophilia B, and von Willebrand’s disease. These conditions are caused by genetic mutations that affect the production or function of certain clotting factors in the blood.

On the other hand, acquired coagulation disorders are caused by external factors that affect the body’s ability to form blood clots. These factors include vitamin K deficiency, liver disease, and disseminated intravascular coagulation (DIC). DIC can also cause thrombocytopenia, which is a condition characterized by low platelet counts in the blood. Another acquired coagulation disorder is acquired haemophilia, which is a rare autoimmune disorder that causes the body to produce antibodies that attack clotting factors in the blood.

It is important to understand coagulation disorders as they can lead to serious health complications such as excessive bleeding or blood clots. Treatment for coagulation disorders varies depending on the underlying cause and severity of the condition. It may include medication, blood transfusions, or surgery. Regular monitoring and management of these conditions can help prevent complications and improve quality of life.

As long as the patient’s Hb level is 7 or higher, transfusion may not be necessary for their management. However, this threshold may vary depending on individual factors such as co-existing medical conditions. It is important to avoid using old blood during massive transfusions as its effectiveness may be compromised.

Blood Products and Cell Saver Devices

Blood products are essential in various medical procedures, especially in cases where patients require transfusions due to anaemia or bleeding. Packed red cells, platelet-rich plasma, platelet concentrate, fresh frozen plasma, and cryoprecipitate are some of the commonly used whole blood fractions. Fresh frozen plasma is usually administered to patients with clotting deficiencies, while cryoprecipitate is a rich source of Factor VIII and fibrinogen. Cross-matching is necessary for all blood products, and cell saver devices are used to collect and re-infuse a patient’s own blood lost during surgery.

Cell saver devices come in two types, those that wash the blood cells before re-infusion and those that do not. The former is more expensive and complicated to operate but reduces the risk of re-infusing contaminated blood. The latter avoids the use of donor blood and may be acceptable to Jehovah’s witnesses. However, it is contraindicated in malignant diseases due to the risk of facilitating disease dissemination.

In some surgical patients, the use of warfarin can pose specific problems and may require the use of specialised blood products. Warfarin reversal can be achieved through the administration of vitamin K, fresh frozen plasma, or human prothrombin complex. Fresh frozen plasma is used less commonly now as a first-line warfarin reversal, and human prothrombin complex is preferred due to its rapid action. However, it should be given with vitamin K as factor 6 has a short half-life.

Docetaxel, a taxane chemotherapy agent, works by reducing the amount of free tubulin through the prevention of microtubule depolymerisation and disassembly during the metaphase stage of cell division, ultimately hindering mitosis.

Cytotoxic agents are drugs that are used to kill cancer cells. There are several types of cytotoxic agents, each with their own mechanism of action and potential adverse effects. Alkylating agents, such as cyclophosphamide, work by causing cross-linking in DNA. However, they can also cause haemorrhagic cystitis, myelosuppression, and transitional cell carcinoma. Cytotoxic antibiotics, like bleomycin and anthracyclines, degrade preformed DNA and stabilize DNA-topoisomerase II complex, respectively. However, they can also cause lung fibrosis and cardiomyopathy. Antimetabolites, such as methotrexate and fluorouracil, inhibit dihydrofolate reductase and thymidylate synthesis, respectively. However, they can also cause myelosuppression, mucositis, and liver or lung fibrosis. Drugs that act on microtubules, like vincristine and docetaxel, inhibit the formation of microtubules and prevent microtubule depolymerisation & disassembly, respectively. However, they can also cause peripheral neuropathy, myelosuppression, and paralytic ileus. Topoisomerase inhibitors, like irinotecan, inhibit topoisomerase I, which prevents relaxation of supercoiled DNA. However, they can also cause myelosuppression. Other cytotoxic drugs, such as cisplatin and hydroxyurea, cause cross-linking in DNA and inhibit ribonucleotide reductase, respectively. However, they can also cause ototoxicity, peripheral neuropathy, hypomagnesaemia, and myelosuppression.

The origin of eosinophils is from common myeloid progenitor cells. A patient with neutrophilia and low haemoglobin is likely to have chronic myeloid leukaemia (CML). CML is characterized by increased levels of all cells derived from the myeloid lineage, including basophils, monocytes, and eosinophils. The bone marrow biopsy is diagnostic for CML and typically shows the t(9;22) chromosomal translocation, also known as the Philadelphia chromosome. Imatinib, an inhibitor of the BCR-ABL fusion protein created with this translocation, is a common treatment for CML. Cells derived from common lymphoid progenitor cells are not affected in CML.

Haematopoiesis: The Generation of Immune Cells

Haematopoiesis is the process by which immune cells are produced from haematopoietic stem cells in the bone marrow. These stem cells give rise to two main types of progenitor cells: myeloid and lymphoid progenitor cells. All immune cells are derived from these progenitor cells.

The myeloid progenitor cells generate cells such as macrophages/monocytes, dendritic cells, neutrophils, eosinophils, basophils, and mast cells. On the other hand, lymphoid progenitor cells give rise to T cells, NK cells, B cells, and dendritic cells.

This process is essential for the proper functioning of the immune system. Without haematopoiesis, the body would not be able to produce the necessary immune cells to fight off infections and diseases. Understanding haematopoiesis is crucial in developing treatments for diseases that affect the immune system.

Angiosarcoma of the liver is a tumor that is not commonly found. However, it has been associated with exposure to vinyl chloride, as seen in this instance. While current factories have taken measures to reduce exposure to this substance, this was not always the case.

Occupational cancers are responsible for 5.3% of cancer deaths, with men being more affected than women. The most common types of cancer in men include mesothelioma, bladder cancer, non-melanoma skin cancer, lung cancer, and sino-nasal cancer. Occupations that have a high risk of developing tumors include those in the construction industry, coal tar and pitch workers, miners, metalworkers, asbestos workers, and those in the rubber industry. Shift work has also been linked to breast cancer in women.

The latency period between exposure to carcinogens and the development of cancer is typically 15 years for solid tumors and 20 years for leukemia. Many occupational cancers are rare, such as sino-nasal cancer, which is linked to wood dust exposure and is not strongly associated with smoking. Another rare occupational tumor is angiosarcoma of the liver, which is linked to working with vinyl chloride. In non-occupational contexts, these tumors are extremely rare.